semaglutide and contrave What's New in Obesity Treatment? Medical Weight Loss - BodyByBariatrics

The MDL encompasses claims involving Ozempic, Wegovy, Saxenda, and Mounjaro, with plaintiffs alleging failures to warn about serious side effects, including NAION, gastroparesis, bowel obstruction, and hair loss

This is where the weight loss results usually become more pronounced as the medication reaches a level that more effectively manages appetite and blood sugar

[18] FDA, Withdrawal of Draft Guidance Documents Published Before December 31, 2013, 80 Fed

Pediatr Res (2025)

Systemic GLP-1 receptor deficiency impairs GLP-1-induced anorexia as anticipated.41 However, these mice do not display alterations in baseline body weight, suggesting that GLP-1 receptor is not critical for body weight regulation under basal conditions.41 Notably, subsequent investigations revealed that both male and female mice lacking systemic GLP-1 receptor are resistant to diet-induced obesity.39,42 Focusing on central mechanisms, intracerebroventricular administration of GLP-1 failed to modulate feeding behavior in GLP-1 receptor global knockout mice.41 Central inhibition of GLP-1 receptor disrupts glucose homeostasis and reduces food intake, whereas peripheral GLP-1 receptor inactivation impairs glucose-stimulated insulin secretion, diminishes glucose clearance, elevates glucagon levels, and accelerates gastric emptying

Novo has said it will limit the initial China launch for Wegovy to avoid global disruption